|
⚲
|
| Keyboard |
| Solas BioVentures Management LLC
✚
|
|
|---|---|
| CRD # | 322344 |
| SEC # | 801-134738 |
| CIK # | |
| AUM | 165.0 M (2026-04-16) |
| Employees | 6 (83% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 423-243-3460 |
| Address | 412 Georgia Avenue Chattanooga, TN 37403 |
| Source | [IAPD] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (7/30/2026) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION In general, Solas receives a management fee and a portion of the carried interest earned by certain General Partners in connection with advisory services provided to the applicable Fund. For more information regarding carried interest distributions in connection with the performance of the Funds, please see Item 6 – Performance-Based Fees and Side by Side Management detailed below. The precise amount, the manner of calculation, and timing of payment of any such management fee, carried interest, or performance-based compensation for each such Fund are established by Solas, as modified by negotiations with limited partners or members (“Investors”) in the applicable Fund, and are set forth in such Fund’s Governing Documents. Nonetheless, the structure of the management fee and carried interest which Solas currently employs, and which Solas expects to employ with respect to future Funds going forward, is summarized below. Management Fees The Funds will pay Solas or its designated affiliate, quarterly in advance for Primary Funds and annually in advance for SPV Funds, a management fee (the “Management Fee”) based on the amount an Investor commits to a Fund (“Subscription”). Management Fees will typically be reduced during the life of a Fund. Investors may be subject to a minimum fee based on an Investor’s Subscription amount. Installments of the Management Fee payable for any period other than a full quarterly or annual period, as applicable, shall be prorated for the actual number of days in such period. In later Primary Funds, the Management Fee attributable to each Investor shall typically be reduced for the quarterly period immediately succeeding the quarterly period in which any transaction fees, break-up fees, director’s fees, advisory fees, monitoring fees, or similar fees or compensation are received by the General Partner, Solas, or any affiliates thereof from one or more Portfolio Companies in such Fund (“Portfolio Fees”) by such Investor’s pro rata share of such Portfolio Fees (net of any applicable taxes and related expenses). If any Investor’s pro rata share of such Portfolio Fees exceeds the Management Fee that is payable by the Fund for the immediately succeeding quarter that is attributable to such Investor, such excess shall be carried forward to reduce the Management Fee attributable to such Investor in successive quarterly periods. If on termination of such Fund, any amount of Portfolio Fees remains that has not been applied to reduce the Management Fee as described above, Solas shall typically cause such amounts to be paid pro rata to Investors who are not in default under the Fund’s Governing Documents (unless such Investor has notified the General Partner in writing that it does not wish to receive such fees). If the Management Fee for a prior fiscal period is increased retroactively as the result of the admission of one or more Investors (“Additional Partners”) to the Fund, at the time of such increase the Fund shall pay to Solas an additional Management Fee equal to the amount of that retroactive increase. Fund Expenses The General Partners and Solas shall be responsible for all of their normal overhead attributable to their activities, including salaries, bonuses and employee benefits of their personnel, office expenses, and office rental and utilities. As set forth in more detail in the applicable Governing Documents, each Fund pays all applicable expenses attributable to the operation of such Fund, which typically includes, but is not limited to or certain to include, the following items: the Management Fee; taxes, fees, and other governmental charges; placement fees (where applicable); activities involving Fund investments (whether or not consummated, and including broken-deal expenses); compliance with federal and state securities laws and any other relevant securities laws, including any relevant filings (CFIUS, etc.); expenses related to portfolio company or Fund personnel, including those affiliated with prospective investment opportunities or partners; litigation, insurance, or other related expenses defending the affairs of the Fund, the General Partner, or any of their respective affiliates; accounting and audit expenses of the Fund and General Partner; research-related expenses; expenses related to the management of Fund assets; software and services used in connection with Fund activities, including the third-party administrator of the Fund and General Partner; all professional expenses for the benefit of the Fund, including the restructuring of relevant documents and the Governing Documents; expenses incurred in connection with securing financing on behalf of the Fund; expenses related to hedging activities; expenses incurred in the formation of special purpose vehicles; costs related to the activities of the Fund’s advisory board and any expenses approved by the advisory board; reasonable travel expenses; and any other expenses as specified in each Fund’s Governing Documents or determined by the General Partner as properly borne by the Fund. In the event any of the Funds incur any common expense, with respect to expenses relating to a specific Portfolio Company, the General Partner shall apportion such expenses amongst the Funds based on the relative amounts invested in such Portfolio Company. With respect to any expense that does not relate to a specific Portfolio Company, the applicable General Partner(s) shall determine each Fund’s proportionate share of such expense based on the aggregate commitments to the capital of each Fund relative to the aggregate commitments to the capital of all other Funds affected or benefited by such expense, or in any other manner such General Partner(s) determines is equitable and appropriate after considering the factors such General Partner(s), in good faith, determines to be relevant. ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (7/30/2026) [Brochure] |
|---|
ITEM 7 – TYPES OF CLIENTS Solas provides investment advisory services to certain private pooled investment vehicles managed by an affiliated General Partner as referenced above in Item 4 – Advisory Business. Generally, Investors in the Solas Funds will be limited to persons or entities which are Accredited Investors and/or Qualified Purchasers (as defined in the Investment Company Act of 1940). Funds have a minimum investment commitment based on each Fund’s Governing Documents; however, Solas has the ability to waive such minimum investment commitment and permit Investors to make commitments that are less than the minimum commitment amount as set forth in the relevant Governing Documents. |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Solas Areteia SPV | 2025-10-10 | 1.8 M | |
| VC | Solas Arrivo B Sidecar | 2025-10-10 | 1.8 M | |
| VC | Solas Basking Holdings | [2025-10-10] | 9.0 M | 9.0 M |
| Filed 2024-07-30 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Solas BioVentures Emerging Healthcare Fund LP | [2025-10-10] | 35.1 M | 48.6 M |
| Filed 2024-05-21 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Solas BioVentures Fund II LP | [2025-10-10] | 35.1 M | 28.7 M |
| Filed 2022-07-05 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Solas BioVentures Fund I LP | 2025-10-10 | 10.6 M | |
| VC | Solas Cryosa Sidecar | [2025-10-10] | 6.9 M | 3.5 M |
| Filed 2024-07-30 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Solas Francis Sidecar | [2025-10-10] | 9.0 M | 31.0 M |
| Filed 2024-07-30 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Solas Intershunt Sidecar | [2025-10-10] | 1.4 M | 1.5 M |
| Filed 2025-01-16 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Solas Maclellan Group JV | 2025-10-10 | 12.3 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 12 | 165.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 12 | 165.0 |
| By Discretionary | ||
| Discretionary | 12 | 165.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 12 | 165.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 165.0 | |
| Total | 12 | 165.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| David Adair | Executive Officer | 29 | 2 | |
| Michael Hoey | Executive Officer | 19 | 2 | |
| David Belitz | Executive Officer | 14 | 2 | |
| Mark Hackett | Executive Officer | 14 | 2 | |
| Charles Adair | Executive Officer | 3 | 2 | |
| Solas BioVentures Management LLC | Promoter | 9 | 1 | |
| Solas Partners II LLC | Promoter | 7 | 1 | |
| Solas BioVentures Emerging Healthcare GP LLC | Promoter | 2 | 1 |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.2B |
| Serves | Institutional |
| Fund Types | Private Equity |
| Comparable Firms | State | AUM |
|---|---|---|
|
Path Capital Partners LLC
✚
|
FL | 169.0 M |
|
Overlay Management LLC
✚
|
GA | 168.6 M |
|
Frontline Healthcare Partners LLC
✚
|
SC | 168.1 M |
|
Norland Capital LP
✚
|
167.5 M | |
|
Wingman Growth Partners LP
✚
|
CT | 167.2 M |
|
Evolution Private Investment Collective LLC
✚
|
CA | 166.5 M |
|
V29 Capital Management LLC
✚
|
166.1 M | |
|
Conifer Infrastructure Management Company LLC
✚
|
PA | 164.8 M |
|
Marquee Capital Advisors LLC
✚
|
IL | 162.7 M |
|
Maple Park Capital Partners Management LP
✚
|
TX | 162.2 M |